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To examine the association between antihypertensive 
treatment and specific adverse events.
Design
Systematic review and meta-analysis.
eligibility criteria
Randomised controlled trials of adults receiving 
antihypertensives compared with placebo or no 
treatment, more antihypertensive drugs compared 
with fewer antihypertensive drugs, or higher blood 
pressure targets compared with lower targets. To avoid 
small early phase trials, studies were required to have 
at least 650 patient years of follow-up.
infOrmatiOn sOurces
Searches were conducted in Embase, Medline, 
CENTRAL, and the Science Citation Index databases 
from inception until 14 April 2020.
main OutcOme measures
The primary outcome was falls during trial follow-
up. Secondary outcomes were acute kidney injury, 
fractures, gout, hyperkalaemia, hypokalaemia, 
hypotension, and syncope. Additional outcomes 
related to death and major cardiovascular events 
were extracted. Risk of bias was assessed using the 
Cochrane risk of bias tool, and random effects meta-
analysis was used to pool rate ratios, odds ratios, and 
hazard ratios across studies, allowing for between 
study heterogeneity (τ2).
results
Of 15 023 articles screened for inclusion, 58 
randomised controlled trials were identified, including 
280 638 participants followed up for a median of 
3 (interquartile range 2-4) years. Most of the trials 
(n=40, 69%) had a low risk of bias. Among seven 
trials reporting data for falls, no evidence was found 
of an association with antihypertensive treatment 
(summary risk ratio 1.05, 95% confidence interval 
0.89 to 1.24, τ2=0.009). Antihypertensives were 
associated with an increased risk of acute kidney 
injury (1.18, 95% confidence interval 1.01 to 1.39, 
τ2=0.037, n=15), hyperkalaemia (1.89, 1.56 to 2.30, 
τ2=0.122, n=26), hypotension (1.97, 1.67 to 2.32, 
τ2=0.132, n=35), and syncope (1.28, 1.03 to 1.59, 
τ2=0.050, n=16). The heterogeneity between studies 
assessing acute kidney injury and hyperkalaemia 
events was reduced when focusing on drugs that 
affect the renin angiotensin-aldosterone system. 
Results were robust to sensitivity analyses focusing 
on adverse events leading to withdrawal from each 
trial. Antihypertensive treatment was associated with 
a reduced risk of all cause mortality, cardiovascular 
death, and stroke, but not of myocardial infarction.
cOnclusiOns
This meta-analysis found no evidence to suggest 
that antihypertensive treatment is associated with 
falls but found evidence of an association with mild 
(hyperkalaemia, hypotension) and severe adverse 
events (acute kidney injury, syncope). These data 
could be used to inform shared decision making 
between doctors and patients about initiation and 
continuation of antihypertensive treatment, especially 
in patients at high risk of harm because of previous 




High blood pressure (hypertension) is one of the leading 
modifiable risk factors for cardiovascular disease 
worldwide,1 and much healthcare resource is given to 
reducing blood pressure. In recent years, guidelines for 
hypertension management have recommended lower 
treatment targets2 3 on the basis of trials that found 
benefit for cardiovascular risk reduction.4 In patients 
with frailty and multimorbidity, however, these 
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WhAt Is AlreAdy knoWn on thIs topIc
Many meta-analyses exist of randomised controlled trials that examine the 
efficacy of antihypertensive treatment, but few have studied potential harms
Existing meta-analyses have focused on the association between antihypertensive 
treatment and all adverse events, grouping mild and more serious outcomes
The association between antihypertensive treatment and specific adverse events 
is unclear
WhAt thIs study Adds
In a meta-analysis of 58 randomised controlled trials, including 280 638 
participants, no evidence was found of an association between antihypertensive 
treatment and falls (primary outcome) or fractures
Evidence was, however, found of an association between antihypertensive 
treatment and potentially both mild (hypotension) and more severe (acute 
kidney injury, syncope) adverse events
These data might be used to inform shared decision making between doctors 
and patients about the benefits and harms of initiation and continuation of 
antihypertensives, especially in those at high risk of harm because of previous 
adverse events or poor renal function
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guidelines recommend clinical judgment because of 
potential risks from adverse effects of treatment.3 5
In the UK, guidelines for managing patients with 
multimorbidity suggest doctors weigh the risk of 
diseases with the benefits and risks of treatments 
and make personalised treatment recommendations.6 
Such an approach is straightforward for the benefits 
of treatment when data exist from numerous meta-
analyses of randomised controlled trials.7-9 When 
attempting to judge the potential harms of treatment, 
however, few data are available to support decision 
making. Existing meta-analyses focus on the overall 
risk of adverse events,10 11 making it difficult to 
distinguish between those events that might not be 
considered particularly serious, such as transient 
electrolyte abnormalities, and those resulting in severe 
complications and hospital admission, such as falls or 
acute kidney injury.
Currently few definitive data are available from 
meta-analyses of randomised controlled trials on the 
risks of specific harm outcomes that could be used to 
facilitate personalised decision making in patients 
with hypertension. We systematically reviewed evi-
dence from trials and large observational studies to 
determine the association between antihypertensive 
treatment and specific adverse events such as falls, 
acute kidney injury, and electrolyte abnormalities.
Methods
We performed a systematic review and meta-analysis 
of randomised controlled trials and large observa-
tional studies examining the association between 
antihypertensive treatment and adverse events. The 
study is reported according to the preferred reporting 
items for systematic reviews and meta-analyses 
(PRISMA) guidelines.12 The study protocol was 
registered on PROSPERO (international prospective 
register of systematic reviews) and is available online 
(www.crd.york.ac.uk/prospero, CRD42018116860).
search strategy
To capture all randomised controlled trials reporting 
the association between antihypertensive treatment 
and adverse events we searched Embase(OvidSP), 
Medline(OvidSP), Cochrane Central Register of 
Controlled Trials (CENTRAL, Cochrane Library), 
and the Science Citation Index (Web of Science Core 
Collection). Searches were undertaken from inception 
of the databases until 14 April 2020, and no language 
restrictions were applied. In this review we focused 
on randomised controlled trials, which are less 
prone to bias from confounding by indication.13  14 
We also searched for large observational studies 
by interrogating the bibliographies of databases of 
electronic health records, but as few relevant data were 
identified and given the limitations of observational 
study designs we decided not to include them in the 
present study. Further studies were identified through 
searching the references of eligible full text articles and 
previous meta-analyses. Supplementary table 1 shows 
the full search strategy.
selection of studies and inclusion and exclusion 
criteria
Eligible studies included participants aged 18 years or 
older, compared individuals receiving antihypertensive 
treatment (single agents) with those receiving placebo 
or no treatment, more antihypertensive drugs compared 
with fewer antihypertensive drugs, or one blood 
pressure target compared with another. Although these 
study designs examine different types of intervention, 
all compared more antihypertensive treatment with 
less antihypertensive treatment, enabling the potential 
association with adverse events to be determined. 
Trials were also required to present data describing 
the association between antihypertensive treatment 
and at least one adverse event. Randomised controlled 
trials were included if they reported 50 or more adverse 
events in each specific category or had at least 650 
patient years of follow-up.
To ensure study selection and data analysis 
remained manageable by avoiding small, early phase 
mechanistic studies, we specified a priori the limit 
on patient years of follow-up and number of outcome 
events. We chose the specific criteria to ensure each 
included study was large enough to accrue outcome 
events and provide reliable effect estimates. These 
criteria assumed an incidence of the primary outcome 
(falls) of 7.8 events per 100 patient years of follow-up, 
which would accrue at least 50 outcome events in each 
study.15
We excluded studies in specialist populations 
(children, pregnant women), and case reports, case 
series, or before and after studies. At least two members 
of the review team (AA, MS, BP, SF, CK, AD, JPS) 
independently reviewed study titles, abstracts, and 
full text articles. At each stage, the entire review team 
screened a proportion of articles to ensure consistency 
of decision making. Disagreements were resolved by a 
third reviewer (JPS).
Outcome measures
Outcomes of interest were prespecified based on those 
reported in recent large scale trials of blood pressure 
lowering treatment.4 16 17 The primary outcome was 
falls, at any time point and by any definition given 
in the original study. Secondary outcomes were acute 
kidney injury, fractures, gout, electrolyte abnormalities 
(changes in potassium), hypotension, and syncope (eg, 
fainting) at any time point during trial follow-up. Acute 
kidney injury was defined as any outcome reported 
according to the KDIGO (kidney disease: improving 
global outcomes) definition.18 All other outcomes were 
defined according to definitions given in the original 
study. Additional treatment efficacy outcomes of 
interest included cardiovascular death, myocardial 
infarction, stroke, and all cause mortality.
Data extraction and quality assessment
AA, MH, LA, AD, and BL extracted data from eligible 
studies. Two reviewers independently entered outcome 
data into a Microsoft Excel spreadsheet (2016 version, 
Redmond, WA). A second reviewer then manually cross 
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checked these, referring to the original source data 
when discrepancies were identified. After an initial 
consistency check involving extraction of data from 10 
articles, one reviewer extracted study descriptive data.
Data were extracted on populations studied, 
interventions tested, length of follow-up, effect 
measures (estimates and confidence intervals for 
rate ratios, odds ratios, and hazard ratios), and 
numbers of patients experiencing adverse events and 
cardiovascular or mortality outcomes.
The methodological quality and risk of bias of 
individual studies was assessed using the Cochrane 
risk of bias tool (for randomised controlled trials).19
Data synthesis
Summary effect estimates describing the association 
between all antihypertensive drug classes (combined) 
and adverse events were derived using a random 
effects meta-analysis. For uncommon adverse events 
(approximately less than 10% of the population 
experience an event), rate ratios (for rate outcomes), 
odds ratios (for binary outcomes), and hazard ratios (for 
time-to-event outcomes) were considered reasonably 
similar and combined provided they had the same 
directional interpretation.20 For uncommon outcomes, 
we label summary effect estimates as risk ratios. For 
more common cardiovascular disease outcomes, we 
synthesised rate ratios, odds ratios, and hazard ratios 
separately. We used restricted maximum likelihood 
estimation to fit the random effects model, with 95% 
confidence intervals derived using the Hartung-Knapp 
approach to account for uncertainty in heterogeneity 
estimates.21 For studies with three treatment arms, 
we split binary and rate outcomes for the control arm 
into two equal groups.22 This approach is not possible 
for the time-to-event outcomes, and therefore we 
made an approximate adjustment to the standard 
errors.
Heterogeneity was summarised using the estimate 
of between study variance (τ2) and 95% prediction 
intervals for the treatment effect in a new study. The 
proportion of variability in effect estimates due to 
between study heterogeneity was summarised using I2.
Sensitivity analyses were undertaken focusing 
on adverse events reported as a reason for study 
withdrawal. Meta-regression was used to examine the 
association between observed treatment effects and 
study quality. Small study effects (potential publication 
bias) were explored using contour enhanced funnel 
plots for outcomes reported in 10 or more studies.23 
Prespecified subgroup analyses were conducted to 
examine the association between treatment and 
adverse events by antihypertensive drug class.
No other subgroup analyses were undertaken by 
patient level characteristics (eg, age), owing to the 
risk of ecological bias.24 Aggregate data only allow 
relationships across studies to be examined, but these 
often do not reflect within study (participant level) 
relationships, because of aggregation bias and study 
level confounding.25 26 For example, those studies 
with a higher mean age might also have a longer 
mean follow-up or a higher dose of the drug; hence it 
is difficult to disentangle these different associations, 
and interpreting across study associations as if they 
were interactions at the individual level is potentially 
misleading.
All analyses were undertaken using Stata version 16 
(StataCorp, College Station, TX).
Patient and public involvement
This study was developed with the help of our patient 
and public advisor. As a member of our study advisory 
group, they commented on the study protocol. We also 
held a focus group with seven older adults during the 
study to discuss broader issues related to drugs for 
cardiovascular disease prevention and adverse events, 
which informed the interpretation of this work.
results
study selection and characteristics
A total of 15 023 unique articles were identified from 
the literature searches, of which 119 records were 
screened from reference lists of included articles and 
previous meta-analyses. After screening of the title, 
abstract, and full text, 63 articles originating from 
58 randomised controlled trials4 16 27-87 were eligible 
for inclusion (fig 1). The most common reason for 
exclusion at full text screening was lack of adverse 
event reporting (n=108) or inclusion of too few patient 
years of follow-up (n=104).
A total of 280 638 participants were included in 
the primary analyses from 58 unique randomised 
controlled trials. Forty eight studies compared a single 
drug treatment with placebo and 10 studies compared 
a high blood pressure target with a lower blood 
pressure target in the intervention and control groups 
(table 1). The remaining five studies either compared 
treatment with no treatment or compared multiple 
drugs with a single drug. The median duration of 
follow-up in the trials was 3 (interquartile range 2-4) 
years. Most studies were conducted in patients with 
at least one risk factor for cardiovascular disease in 
addition to hypertension.
Quality assessment
Supplementary table 2 presents the risk of bias 
assessment for individual trials. Most of the trials 
(n=40, 69%) had a low risk of bias (fig 2). Eight trials 
(14%) did not adequately blind outcome assessment 
of adverse events (or did not describe this adequately) 
and 12 (21%) did not adequately describe the 
randomisation process. Outcome reporting was 
complete in 52 trials (90%) trials.
Primary outcome
Seven randomised controlled trials reported data for 
the primary outcome of falls (fig 3). Data were availa-
ble from 29 481 patients experiencing 1790 events. 
Overall, no evidence was found of an association 
between antihypertensive treatment and falls 
(summary risk ratio 1.05, 95% confidence interval 
0.89 to 1.24). Little evidence was found of between 
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study heterogeneity in this association (τ2=0.009; 
I2=31.5%; P=0.372). Subgroup analyses by drug type 
did not reveal any evidence of associations between 
falls and specific antihypertensive drug classes, except 
for thiazide diuretics, although this was based on 
data from just one trial (supplementary figure 1).71 
More intensive treatment (ie, to lower blood pressure 
targets) was not associated with falls across four trials 
(supplementary figure 1).
secondary outcomes
In analyses examining adverse events across all drug 
classes, antihypertensive treatment was associated 
with an increased risk of acute kidney injury (summary 
risk ratio 1.18, 95% confidence interval 1.01 to 1.39, 
n=15 studies; fig 4), hyperkalaemia (1.89, 1.56 to 
2.30, n=26 studies), hypotension (1.97, 1.67 to 2.32, 
n=35 studies), and syncope (1.28, 1.03 to 1.59, 
n=16 studies) (table 2; supplementary figures 2-4), 
although statistical heterogeneity was significant 
for most outcomes (τ2=0.037 to 1.374; I2=42.9% 
to 85.1%). Evidence was unclear of an association 
between antihypertensive treatment and fractures 
(0.93, 0.58 to 1.48, τ2=0.062, I2=53.8%, n=5 studies; 
supplementary figure 5) and gout (1.54, 0.63 to 3.75, 
τ2=1.612, I2=94.3%, n=12 studies; supplementary 
figure 7), although confidence intervals were wide, 
partly reflecting large between study heterogeneity.
Analyses of outcomes by specific drug class showed 
that drugs affecting the renin angiotensin-aldosterone 
system were associated with acute kidney injury (1.26, 
1.03 to 1.56, τ2=0.030, I2=39.0%; n=9 studies; table 
3, supplementary figure 8) and hyperkalaemia (2.03, 
1.67 to 2.48, τ2=0.063, I2=51.0%; n=20 studies; 
table 3, supplementary figure 9). These effects were 
larger and had less between study heterogeneity than 
in analyses examining the association between all 
antihypertensive treatments and the same outcomes 
(table 2 and table 3). Only a small number of studies 
assessed the association between diuretics and 
hypokalaemia (three studies) or gout (five studies), 
and the results of these were inconclusive (table 3; 
supplementary figures 10 and 11). No other drug 
class specific associations with adverse events were 
observed in the stratified analyses (supplementary 
figures 12-14).
cardiovascular and mortality outcomes
On average across studies examining outcomes using 
time-to-event analyses, antihypertensive treatment 
was associated with a reduction in cardiovascular 
death (hazard ratio 0.92, 95% confidence interval 
0.86 to 0.99, τ2=0.011, I2=54.6%, n=21 studies; fig 
5), all cause mortality (0.93, 0.88 to 0.98, τ2=0.008, 
I2=50.4%, n=32 studies; supplementary figure 15), 
and stroke (0.84, 0.76 to 0.93, τ2=0.013, I2=44.8%, 
Additional records identified
through other sources*
Full text articles excluded
No adverse events reported
Too few events or patient years of follow-up
Wrong outcome
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fig 1 | selection of studies for inclusion in review. *Hand searches of reference lists of included studies and recent 
meta-analyses of blood pressure lowering trials7-9
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n=17; supplementary figure 16) (table 2). No clear 
evidence was found of an association between 
antihypertensive treatment and myocardial infarction 
(supplementary figure 17).
sensitivity analyses
Meta-regression examining the relation between the 
observed treatment effects for each adverse event 
outcome and study quality found no clear evidence of 
an association (supplementary table 3). Funnel plots 
showed asymmetry (potential publication bias) for 
hyperkalaemia and hypotension events, with smaller 
studies missing for smaller effect estimates, but this 
was not evident for other adverse events examined 
(supplementary figures 18-22).
Supplementary figures 23-27 show the results of 
sensitivity analyses focusing on studies reporting 
adverse events that led to participant withdrawal from 
each trial (summarised in table 4). These analyses were 
limited to studies reporting acute kidney injury, gout, 
hyperkalaemia, hypotension, and syncope owing to 
availability of data. In these analyses, summary risk 
ratios for hyperkalaemia, hypotension, and syncope 
were increased compared with the primary analysis 
including all studies. However, there was no longer 
evidence that acute kidney injury was associated with 
antihypertensive treatment (table 4).
discussion
Data from random effects meta-analyses of 58 
randomised controlled trials and more than 280 000 
patients with hypertension confirm the known benefit 
of antihypertensive treatment in reducing the risk of 
cardiovascular disease.7-9 These data also confirm the 
association between antihypertensive treatment and 
adverse events10 11 and show how this association 
varies across some drug classes and for mild (eg, 
hypotension without falls) and more severe (eg, 
acute kidney injury, syncope) adverse events. Despite 
a widely held belief,95 96 no association was found 
between treatment and falls, but an association with 
syncope was observed, which is important as this 
can have a major impact on quality of life and health 
service use and could even result in death.97-100
These data will inform shared decision making 
around initiation and continuation of antihypertensive 
treatment, especially in patients with a high absolute 
risk of certain adverse outcomes as a result of previous 
events or poor renal function. Such discussions will 
become increasingly important as patients age and 
develop frailty and multimorbidity that could put them 
at increased risk of adverse events.101-103
strengths and limitations of this study
More than 15 000 articles were screened for inclusion 
in this review and 58 randomised controlled trials 
including a large number of participants and adverse 
events were identified. Although power was likely 
to be sufficient to detect associations between 
antihypertensive treatment and adverse events, we 
observed statistically significant heterogeneity across 
studies, and the resulting prediction intervals were 
wide. Such heterogeneity might preclude pooling of 
some treatment effects, so caution should be exercised 
when interpreting the results. For acute kidney injury 
and hyperkalaemia events, the observed heterogeneity 
was partly explained by pooling of different drug 
classes, and heterogeneity was reduced when we 
focused on drugs that affect the renin angiotensin-
aldosterone system. For other outcomes, the observed 
heterogeneity could not be explained by study quality 
or differences in the drug class examined in individual 
trials; however, populations of interest, interventions, 
comparators, and study designs varied widely across 
studies, which could have contributed to the observed 
variation.
As this review focused on adverse events, selective 
outcome reporting might also have been a problem. 
Evidence was found of publication bias for certain 
outcomes (hyperkalaemia and hypotension), confir-
ming the findings of previous studies that showed 
adverse events are more likely to be reported in 
randomised controlled trials when they are statistically 
significant.104 This is understandable in the context 
of single trial reporting, but it would be better for the 
evidence base if all adverse events were reported in 
clinical trials to enable more complete meta-analyses 
in the future. It is a limitation of this review that 
original study authors were not contacted for these 
additional data.
This review focused on large randomised controlled 
trials with the aim of including those with at least 
50 adverse events (and therefore 650 patient years 
of follow-up). This restriction on study size was 
chosen to make the review more manageable in 
terms of screening and analysis and avoid inclusion 
of numerous small early phase mechanistic studies 
of varying methodological quality. The cut-off for 
this inclusion was chosen to ensure studies provided 
adequately powered estimates of association between 
treatment and outcomes.15 It is possible that some 
useful trials could have been excluded, although many 
relevant trials were still available for inclusion.
Across all included trials, adverse events were 
poorly defined and probably varied across studies. 
For instance, many studies referred to syncope as an 
outcome, but did not say what type of syncopal event 
this might have included. A conservative approach 
to inclusion of outcomes was taken when possible, 
and only those explicitly stating the outcome of 
interest were included. For example, trials reporting 
hypotension or acute kidney injury were included, 
but those reporting hypotension or dizziness or renal 
impairment were excluded. Despite this approach, 
some studies were included that did not specify the 
thresholds used to define hypotension or acute kidney 
injury. This could have resulted in some relevant data 
for certain outcomes being missed, but this meant 
those that were included were likely to be sufficiently 
similar to enable pooling in a meta-analysis. Although 
the quality of adverse event ascertainment is likely to 
have varied between trials, it would not be expected 
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mean (sD) age  
(years): intervention; 
control
mean (sD) baseline sbP 
(mm Hg): intervention: 
control intervention comparator
AASK 200237 African-Americans with  
renal disease
1094 3.8 years 54.5 (10.9);  
54.7 (10.4)
152 (25); 149 (23) Mean atrial pressure 
target ≤92 mm Hg
Mean atrial  
pressure target  
102-107 mm Hg
ACCORD 201016 48 Type 2 diabetes 4733 5.6 years 62.2 (6.8); 62 (6.9) 139.0 (16.1) 139.4 (15.5) BP target  
<120 mm Hg
BP target  
<140 mm Hg
ACEi progressive renal  
insufficiency study  
group 199659
Renal dysfunction 583 3 years 51 (13); 51 (12) 142 (17); 144 (17)
Benazepril Placebo
ADVANCE 201470 Type 2 diabetes 11 140 4.3 years 66 (6); 66 (7) 145 (22); 145 (21) Perindopril 
+indapamide Placebo
AIRE 199381 Acute myocardial infarction 
+evidence of heart failure
1986 15 months 64.9 (10);  
65.1 (10.8)
NS (28% hypertensive) Ramipril Placebo
ALTITUDE 201285 Type 2 diabetes 8561 2.6 years 64.6 (9.6); 64.4 (9.9) 137.3 (16.2); 137.3 (16.7) Aliskiren Placebo
ASPIRE 201186 Post-myocardial infarction 820 36 weeks 61 (12); 59 (12) 121.6 (16.1); 121.7 (16.2) Aliskiren Placebo
BEST 200187 NYHA class III or IV heart failure 2708 2 years 60 (12.6); 60 (12.3) 117 (18.2); 117 (17.8) Bucindolol Placebo
BHAT 198227 Admitted to hospital with acute 
myocardial infarction
3837 2 years 54.7 (NS); 54.9 (NS) 112.3 (NS); 111.7 (NS) Propranolol Placebo
Cardio-Sis 200928 No diabetes with  
hypertension
1111 2 years 67 (7); 67 (7) 163.3 (11.3); 163.3 (11.1) BP target  
<120 mm Hg
BP target  
<130 mm Hg
CCS-I 199729 Acute myocardial infarction 14 962 4 weeks 61.2 (10.7); 61 (10.6) 127 (24); 126 (24) Captopril Placebo
CHARM -Preserved  
200330
NYHA class II-IV  
heart failure
3023 Median  
36.6 months
67.2 (11.1);  
67.1 (11.1)
136.0 (18.6);  
136.3 (18.3) Candesartan Placebo
CHARM-ADDED 200331 NYHA class II-IV heart failure 2548 3.5 years 64 (10.7); 64.1 (11.3) 124.7 (18.6); 125.6 (18.6) Candesartan Placebo
CHARM-Alternative 
200332
Heart failure 2028 2.7 years 66.3 (11); 66.8 (10.5) 129.9 (19.0); 130.3 (18.5) Candesartan Placebo
Collaborative Study  
Group 200133
Type 2 diabetes  
with nephropathy
1715 2.6 years 59.3 (7.1), 59.7 (7.9); 
58.3 (8.2)




CONSENSUS II 199234 Post-myocardial infarction 6090 6 months 65.7 (NS); 65.8 (NS) 133 (NS); 134 (NS) Enalapril Placebo
DIME 201435 No diabetes, hypertension 1130 4.4 years 63 (10); 63 (10) 154 (11); 154 (10) Thiazide diuretic No thiazide diuretic
Dutch TIA Trial 199336 Previous transient  
ischaemic attack
1473 2.6 years 50 (NS); 54 (NS) 157 (25) and 158 (24) Atenolol Placebo
EMPHASIS-HF 201138 NYHA class II heart failure 2737 1.75 years 68.6 (7.7); 68.6 (7.6) 124 (17); 124 (17) Eplerenone Placebo
EUROPA 200339 Stable coronary heart disease 
without heart failure
12 218 4.2 years 60 (9); 60 (9) 137 (16); 137 (15) Perindopril Placebo
EWPHE 199140 >60 years with raised BP 822 5 years 72 (8); 72 (8) 183 (16); 183 (16) Hydrochlorothi-
azide+triamterene Placebo
GISSI-3 199441 Myocardial infarction  
within 24 hours
9442 6 weeks NS NS Lisinopril No treatment
GISSI-AF 200942 Atrial fibrillation and  
underlying CVD
1442 1 year 67.5 (9.5); 68.2 (8.9) 138.2 (16.7);  
139.0 (16.9) Valsartan Placebo
Hypertension in  
diabetes study IV 199643
Type 2 diabetes 758 5 years 57 (7.9) all patients 160 (19); 160 (20) Atenolol or Captopril 
with BP target 
<150/<85 mm Hg
BP target  
<180/ 
<105 mm Hg
HOPE Trial44 45 >55 years, high CVD risk 9297 5 years 66 (7); 66 (7) 139 (20); 139 (20) Ramipril Placebo
HOPE-3 201646 Men >55 years and women  
>65 years with one CVD risk 
factor or more
12 705 5.5 years 65.7 (6.4); 65.8 (6.4) 138.2 (14.7);  
137.9 (14.8) Candesartan +Hydrochlorothiazide Placebo
HYVET Trial47 84 >80 years with hypertension 3845 2.1 years 84/84 173 and 173 Indapamide and/or 
perindopril Placebo
INFINITY 201949 >75 years, hypertension,  
white matter lesions
199 3 years 80.9 (4.4); 80.3 (3.8) 149.7 (15.4);  
152.0 (17.5)
sBP target  
≤130 mm Hg




Treatment for Elderly 
201350
>70 years with hypertension 724 4 years 76.6 (4.6); 76.5 (4.5) 158.8 (16.0);  




I-PRESERVE 200851 Heart failure 4128 4.1 years 72 (7); 72 (7) 137 (15); 136 (15) Irbesartan Placebo
MACB 199552 Referred for coronary artery 
bypass grafting
967 2 years Median age 64 in both 
groups
Median sBP 120 mm Hg  
in both groups Metoprolol Placebo
MERIT-HF 200053 NYHA class II-IV  
heart failure
3991 1 year 63.9 (NS); 63.7 (NS) Not stated (44% of cohort 
hypertensive) Metoprolol Placebo
MRC 198555 Patients with mild  
hypertension
17 354 5.5 years 51 (NS); 53 (NS) 158 (men); 165 (women) Bendroflumethiazide  
or propranolol Placebo
Multicentre Diltiazem  
Postinfarction Trial 
198856
Admitted to hospital with  
acute myocardial infarction
2466 25 months 58 (10); 58 (10) NS
Diltiazem Placebo
NAVIGATOR 201057 Type 2 diabetes 9306 6.3 years 63.7 (6.8) 63.8 (6.8) 139.4 (17.8) and 139.9 
(17.1) Valsartan Placebo
NICOLE 200358 <75 years and previous  
successful angioplasty
819 3 years 60.4 (NS); 60.2 (NS) NS (40% of cohort  
hypertensive) Nisoldipine Placebo
NILVAD 201860 Alzheimer’s disease 511 1.5 years 73.1 (8.7); 72.8 (7.8) 138 (14); 137 (14) Nilvadipine Placebo
table 1 | summary of included randomised controlled trials
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to vary between treatment arms within trials. Thus it 
is unlikely that differences in the quality of adverse 
event ascertainment would have affected the relative 
treatment effects presented in this review.
We prespecified adverse events of interest based 
on those reported in recent large scale trials of blood 
pressure lowering treatment.4 16 17 Other patient 
focused harm outcomes, such as weight gain, sexual 
dysfunction, fatigue, and exercise intolerance might 
exist that were reported in the original trials but not 
captured as part of this review. However, the reporting 
of these events is likely to vary because many have 
no standardised definitions.105-107 Some might be 
captured but not reported.108 It is also important to 
note that randomised controlled trials often select 
populations with less frailty and multimorbidity who 
are more likely to tolerate treatment.109 Therefore, 
fewer adverse events might have been reported in the 
included trials than would be expected in the general 
population.
For outcomes included in meta-analyses, the time 
points at which they occurred varied across studies, 
and so the risk ratios and odds ratios provided relate 
to a summary across different times. We did synthesise 
hazard ratios when available, but these were rarely 
reported.
comparison with other studies
Few previous meta-analyses have quantified the 
association between antihypertensive treatment 
and adverse events. Thomopoulos and colleagues 
examined the association between antihyperten-
sive treatment and permanent discontinuation of 
treatment because of adverse events and found 
that antihypertensives were associated with a near 
doubling of risk (standardised relative risk 1.89, 95% 
confidence interval 1.51 to 2.39).10 110 This was similar 
to findings from our sensitivity analyses focusing on 
permanent withdrawal as a result of hyperkalaemia, 
hypotension, and syncope events. These associations 
were stronger than those observed in the primary 
analysis focusing on all adverse event reporting. It 
is possible that these events were more likely to be 
reported in the intervention group when they were 
table 1 | continued






mean (sD) age  
(years): intervention; 
control
mean (sD) baseline sbP 
(mm Hg): intervention: 
control intervention comparator
ONTARGET 200861 Existing vascular  
disease or diabetes
25 620 4.5 years 66.4 (7.2) 66.4 (7.1) 
66.5 (7.3)
141.8 (17.4); 141.7 (17.2); 




ORIENT 201162 Type 2 diabetes with  
poor renal function
566 3.4 years 59.1 (8.1)/; 59.2 (8.1) 141.7 (17.0) 140.8 (18.0) Olmesartan Placebo
PEACE 200463 Myocardial infarction or bypass 
in past 3 months
8290 4.8 years 64 (8); 64 (8) 134 (17) and 133 (17) Trandolapril Placebo
PRoFESS 200864 >55 years and ischaemic stroke 20 332 2.5 years 66.1 (8.6); 66.2 (8.6) 144.1 (16.4) 144.2 (16.7) Telmisartan Placebo
PROGRESS 200165 Previous stroke or transient 
ischaemic attack
6105 4 years 64 (10); 64 (10) 147 (19); 147 (19) Perindopril 
+indapamide Placebo
ROADMAP Trial66 67 Type 2 diabetes 4447 3.2 years 57.7 (8.8); 57.8 (8.6) 137 (16); 136 (15) Olmesartan Placebo
SANDS 200968 Native Americans  
with type 2 diabetes




SENIORS 200569 >70 years with heart failure 2128 1.5 years 76.1 (4.8); 76.1 (4.6) 138.6 (20.1) 139.5 (21.1) Nebivolol Placebo
SHEP 199171 72 >60 years with ISH 4736 5 years 71.6 (6.7); 71.5 (6.7) 170.5 (9.5) 170.1 (9.2) Chlorthalidone with 
or without atenolol or 
reserpine
Placebo
SOLVD 199273 Heart failure with ejection 
fraction <0.35
2569 41.4 months 60.7 (NS); 61.0 (NS) 125.3 (NS); 124.5 (NS) Enalapril Placebo
Spironolactone and  
mild heart failure 201674




SPRINT 20154 >50 years with increased CVD 
risk, no diabetes
9361 3.26 years 67.9 (9.4); 67.9 (9.5) 139.7 (15.8); 139.7 (15.4) BP target  
<120 mm Hg
BP target <140 
mm Hg
SPS3 201375 Stroke within past 6 months 3020 3.7 years 63 (11); 63 (11) 142 (19); 144 (19) BP target  
<130 mm Hg
BP target  
130-149 mm Hg
The Norwegian  
Multicenter Study 198176
Admitted to hospital with acute 
myocardial infarction
1884 17 months 60.3 (NS); 61.4 (NS) NS Timolol Placebo
TRACE 199586 Admitted to hospital with acute 
myocardial infarction
1749 24 to 50 
months
67.7 (NS); 67.3 (NS) 122 (NS); 120 (NS) Trandolapril Placebo
TRANSCEND 200877 CVD or diabetes with  
end organ damage
5926 Median 56 
months
66.9 (7.3); 66.9 (7.4) 140.7 (16.8); 141.3 (16.4) Telmisartan Placebo
TROPHY 200678 Prehypertensive population 772 4 years 48.6 (7.9); 48.3 (8.2) 133.9 (4.3); 134.1 (4.2) Candesartan Placebo
VA NEPHRON-D 201379 Type 2 diabetes+moderate to 
severe proteinuria
1448 2.2 years 64.5 (7.9); 64.7 (7.7) 136.9 (16.5); 137.0 (16.0) Losartan+lisinopril Losartan+placebo
Val-HeFT 200180 Heart failure 5010 23 months 62.4 (11.1) 63.0 (11) 123.0 (18.4) 124.0 (18.6) Valsartan Placebo
VALIANT 200382 Myocardial infarction with left 
ventricular systolic dysfunction
11 703 2 years 65.0 (11.8) 64.9 (11.8) 
64.6 (11.9)





VA-NHLBI 197883 21-50 years with mild hyper-
tension




CVD=cardiovascular disease; NYHA=New York Heart Association; NS=not stated; sBP=systolic blood pressure; ISH=isolated systolic hypertension.
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considered serious enough to lead to withdrawal.104 
Although the focus of this review was on adverse 
events, we found evidence for the beneficial effects 
of treatment on all cause mortality, cardiovascular 
mortality, and stroke, but not on myocardial infarction, 
as has been reported previously.4 8
Frey and colleagues11 focused on data from seven 
original studies investigating the harms of intensive 
blood pressure lowering targets (≤130 mm Hg) versus 
usual care (<140 mm Hg). Although this number of 
studies was insufficient to conduct a meta-analysis, the 
descriptive summary suggested that intensive blood 
pressure lowering might be associated with higher 
rates of serious adverse events. The present analysis 
included all trials of blood pressure lowering treatment 
enabling meta-analyses of the association between 
antihypertensive treatment and adverse events and 
how this association varies across mild and more 
severe adverse events. We identified an increased risk 
of acute kidney injury, hyperkalaemia, hypotension, 
and syncope with antihypertensive treatment.
Stratified analyses by drug class suggested 
that associations with acute kidney injury and 
hyperkalaemia were mostly driven by the use of drugs 
that affect the renin angiotensin-aldosterone system (eg, 
angiotensin converting enzyme inhibitors, angiotensin 
II receptor blockers, and direct renin inhibitors). 
However, no evidence was found of an association 
with this class of drug and falls, fractures, gout, or 
hypokalaemia. In analyses that focused on patients 
prescribed diuretics, a 10-fold increase in the risk of 
hypokalaemia was observed, but this association was 
derived from only three trials, with high between study 
heterogeneity. The pooled effect had large confidence 
intervals and was not statistically significant. This 
null finding contrasted with previous studies that 
recommend routine monitoring of potassium to detect 
hypokalaemia in patients prescribed diuretics.111 This 
could be explained by the small number of included 
trials examining this drug class.
Much debate exists in the literature on the 
association between antihypertensive treatment and 

















































































fig 2 | summary of risk of bias assessment across all included randomised controlled 
trials
Binary outcomes
  ACCORD 2010
  ALTITUDE 2012
  INFINITY 2019
  NILVAD 2018
  SHEP 1991
  SPS3 2013
Subgroup: I2=34.2%
  with estimated prediction interval
Time to event outcomes
  SPRINT 2015
Heterogeneity between groups: P=0.372
Overall: I2=31.5%
  with estimated prediction interval
0.94 (0.79 to 1.12)
1.09 (0.84 to 1.42)
0.93 (0.52 to 1.66)
1.09 (0.67 to 1.76)
1.26 (1.06 to 1.51)
0.14 (0.01 to 2.73)
1.07 (0.88 to 1.31)
 (0.74 to 1.55)
0.95 (0.73 to 1.23)
1.05 (0.89 to 1.24)











































fig 3 | random effects meta-analysis of randomised controlled trials examining the association between 
antihypertensive treatment and falls
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originate from observational studies,112 113 which 
are prone to bias from confounding by indication.14 
Despite conflicting evidence, a wide held belief 
remains that antihypertensive treatment increases 
the risk of falls.95 96 This study found no evidence 
for an association between treatment or lower blood 
pressure targets and falls, but an association was 
found with syncope. Although syncope is a common 
cause of falls, not all falls are caused by syncope and 
therefore not all falls will be related to blood pressure 
lowering treatment.114 In addition, reporting of falls 
might vary among participants (ie, not all participants 
will be admitted to hospital or see their primary care 
doctor after a fall) and participants might be more 
likely to be withdrawn from a trial when experiencing 
events that could be considered precursors to falls 
and fractures (eg, hypotension). If this were the case 
and hypotension events are not dealt with by treating 
doctors, the incidence of serious falls and fractures 
associated with antihypertensive treatment could be 
greater in routine clinical practice.
Policy implications
The present data clearly show the benefits and harms of 
antihypertensive treatment for specific cardiovascular 
outcomes and adverse events. The data also highlight 
that certain adverse events might be specific to certain 
drug classes (eg, renin angiotensin-aldosterone system 
drugs and acute kidney injury or hyperkalaemia). 
This detail is important because some adverse events 
reported in randomised controlled trials might be 
considered relatively mild and worth the risk when 
weighed against the substantial benefits of treatment. 
These new data will allow patients and clinicians to 
take into consideration these benefits and risks, as 
has been recommended in clinical guidelines.6 This 
is particularly important now that guidelines for the 
management of hypertension across the world increa-
singly recommend more intensive treatment,2 3 5 115 
but with conflicting blood pressure targets, meaning 
a personalised approach is required for each patient.
The present data should ideally be combined with 
information about an individual’s absolute risk of 
each harm outcome to make informed, personalised 
treatment decisions. This process is complex and 
requires real time data, which suggests that tools 
embedded in electronic health records will be the way 
forward. Further work is needed to understand better 
the results of this meta-analysis (which summarises 
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  EUROPA 2003
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  ORIENT 2011
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Subgroup: I2=0%
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fig 4 | random effects meta-analysis of randomised controlled trials examining the association between antihypertensive treatment and acute 
kidney injury
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in the context of individualised absolute risks so 
that treatment initiation and discontinuation can 
be targeted at those with the most to gain.116 In the 
absence of such information, doctors should focus 
on patients who have experienced previous adverse 
events or have poor renal function.17 110 117
conclusions
This review found no evidence of an association 
between antihypertensive treatment and falls (primary 
outcome) or fractures but did show a variation in the 
association between antihypertensive treatment and 
mild (eg, hypotension without falls) and more severe 
(eg, acute kidney injury, syncope) adverse events. 
Some effects were found to be specific to the drug class 
used. In patients at high risk of drug harms because of 
previous adverse events or poor renal function, these 
data should be used to inform shared decision making 
between doctors and patients around initiation and 
continuation of antihypertensive treatment.





no of  
studies
sample size events
risk ratio  











Acute kidney injury33 39 51 
61 62 64 79 81 85 RAAS 9 33 686 42 316 514 468
1.26  
(1.03 to1.56) 39.0 0.030 0.80 to 1.99
Hyperkalaemia30-34 42 45 
51 57 59 62 64 73 77 79 82 85 
86 91-93
RAAS 20 47 122 51 787 2282 1541 2.03  (1.67 to 2.48) 51.0 0.063 1.16 to 3.57
Hypokalaemia35 71 72 83 Diuretics 3 3154 3114 259 25 10.73  (0.32 to 354.58) 80.9 1.385 -
Gout17 35 55 71 72 83 90 Diuretics 5 12 121 12 190 237 29 4.48  (0.79 to 26.54) 85.0 1.547 0.05 to 388.68
RAAS=drugs affecting the renin angiotensin-aldosterone system (eg, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, direct renin inhibitors); diuretics=thiazide and 
thiazide-like diuretics.
Other generic adverse events such as falls, hypotension, syncope, and fractures were examined by drug class, but no significant drug specific effects were observed (supplementary figures 1 and 
12-14).
table 2 | main analyses showing meta-analysis results from trials reporting the association between antihypertensive treatment and adverse events 
and cardiovascular and mortality outcomes
Outcome
no of  
studies
sample size events effect size  
(95% ci)* i2 (%) τ2
95% prediction 
intervalintervention group control group intervention group control group
adverse events
Falls4 16 49 60 71 72 75 85 
(primary outcome) 7 14 719 14 762 913 877
1.05  
(0.89 to 1.24) 31.5 0.009 0.77 to 1.43
Acute kidney injury4 16 33 
38 39 51 61 62 64 68 79 81 85 88 15 43 467 52 133 909 785
1.18  
(1.01 to 1.39) 48.1 0.037 0.76 to 1.85
Fractures16 50 60 71 72 89 5 6447 6466 230 267 0.93  (0.58 to 1.48) 53.8 0.062 0.36 to 2.41
Gout17 35 55 83 90 5 16 524 16 137 249 26 3.84  (0.95 to 15.57) 84.3 1.374 0.11 to 138.91
Hyperkalaemia4 16 30-34 38 
41 43 45 51 57 59 62 64 68 73 74 
77 79 82 85 86 91-93
26 57 604 61 795 2749 1880 1.89  (1.56 to 2.30) 71.8 0.121 0.90 to 3.98
Hypokalaemia4 16 35 38 43 
51 57 71 72 74 83 86 94 12 19 748 19 528 517 274
1.54  
(0.63 to 3.75) 94.3 1.612 0.08 to 29.98
Hypotension4 16 27 29-32 34 
36 38 39 42 51-53 56 58 62 64 65 
68-70 75 76 78 80-82 85-87 91 93
35 88 575 93 547 5390 3121 1.97  (1.67 to 2.32) 85.1 0.132 0.92 to 4.18
Syncope4 16 17 27 60 61 63 64 
68 75-78 81 85 87 16 51 072 51 189 644 543
1.28  
(1.03 to 1.59) 42.9 0.050 0.75 to 2.17
cardiovascular and mortality outcomes
All cause mortality4 16 
17 28 31 32 34 36 38 42 56 57 
62 63 69 71 72 74 75 77 79-81 
85-87 89 91
32 128 619 128 729 11 831 13 018 0.93  (0.88 to 0.98) 50.4 0.008 0.77 to 1.12
Cardiovascular death4 16 
17 30-32 36 45 51 57 61-63 69 71 
72 75 77 82 85 87 91 92
21 92 676 92 733 6341 6890 0.92  (0.86 to 0.99) 54.6 0.011 0.73 to 1.16
Myocardial infarction4 16 
17 28 32 38 45 57 61-63 71 72 75 
77 79 85 87 89 91 92
19 75 002‬ 75 301 2900 3255 0.94  (0.85 to 1.03) 40.7 0.013 0.73 to 1.21
Stroke4 16 17 28 36 38 45 57 
61-64 75 77 79 85 89 92 17 104 153 104 366 3220 3733
0.84  
(0.76 to 0.93) 44.8 0.013 0.64 to 1.09
*Adverse events reported as risk ratios and cardiovascular and mortality outcomes reported as hazard ratios (in studies reporting outcome as time to event). Binary and rate outcomes for 
cardiovascular and mortality outcomes are presented in supplementary figures 15-17.
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table 4 | sensitivity analyses showing meta-analysis results focusing on trials reporting the association between antihypertensive treatment and 
adverse events which led to permanent withdrawal from a trial
Outcome
no of  
studies
sample size events
risk ratio  











Acute kidney injury38 39 61 62 64 85 6 30 672 39 350 128 146 1.34 (0.99 to 1.81) 0.0 0.000 0.97 to 1.84
Gout17 55 2 15 998 15 959 179 38 3.41 (0.08 to 148.47) 86.4 1.903 -
Hyperkalaemia30-34 38 42 45 59 62 64 82 85 92 13 34 580 38 953 398 189 2.28 (1.70 to 3.05) 22.8 0.053 1.28 to 4.06
Hypotension27 30-32 34 38 39 42 52 53 62 64 65 
70 76 80 82 85 18 51 063 56 030 1042 541 2.18 (1.84 to 2.58) 34.0 0.033 1.43 to 3.32
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fig 5 | random effects meta-analysis of randomised controlled trials examining the association between antihypertensive treatment and 
cardiovascular death
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